December 22, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Eisai Launches Programs to Help Eliminate Lymphatic Filariasis By 2020
 

Tokyo, Jan 31, 2012 (JCN) - In line with its commitment to support the World Health Organization's lymphatic filariasis elimination program, Eisai Co., Ltd, as one of the 13 major research and development-based pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S. and U.K. governments, the World Bank and governments from neglected tropical disease (NTD)-endemic countries, gave its support on January 30 (local London time) to the London Declaration, a coordinated effort to eliminate 10 NTDs by the end of this decade.

Eisai is committed to taking proactive steps to address issues related to access to medicines, including NTDs, in accordance with established policy as it expands its business in both emerging and developing nations in this era of great globalization. The company considers its contributions to the economic development and expansion of the middle-income class through the enhancement of health and welfare in these countries as a form of long-term investment for future growth.

Eisai is the only Japanese company to join this coordinated program. In support of the London Declaration and the WHO's program to eliminate lymphatic filariasis, Eisai has signed an agreement with the WHO to extend its support until 2020, during which Eisai will supply free of charge 2.2 billion tablets of the medicine DEC (diethylcarbamazine) until 2020, in line with the WHO elimination goals.

Eisai will start manufacturing DEC in accordance with the high quality standards of WHO at its plant in Vizag, India, and provide it to people in need as a price "zero" Eisai product, while working on the collection and provision of relevant safety information to ensure the appropriate use of the medicine. Eisai will begin supplying DEC from 2013, and plans to deliver this medicine to some 250 million people in the developing world by 2020.

Eisai has also committed to provide 120 million DEC tablets to the WHO free of charge in collaboration with Sanofi and the Bill & Melinda Gates Foundation to ensure a stable of supply of DEC until 2013 when the Eisai-produced DEC becomes available. This is the first partnership in which two pharmaceutical companies, with the Gates Foundation, have come together to supply a single drug for an NTD.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Eisai News  
  Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment  (Dec 17, 2014)
  Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia  (Dec 10, 2014)
  Eisai Presents Results from Phase III Trial of Antiepileptic Drug Fycompa as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures  (Dec 9, 2014)
  Eisai to Present New Research on Halaven (Eribulin) at 37th Annual San Antonio Breast Cancer Symposium  (Dec 2, 2014)
  Eisai Establishes Holding Company Eisai China Holdings Ltd. in China  (Dec 1, 2014)
  Eisai Opens New Parenteral Facility in China  (Dec 1, 2014)
  Eisai Opens New Packaging Facility at Hatfield Production Plant in U.K.  (Nov 28, 2014)
  Eisai Launches Anticancer Agent Halaven as Company's First Product in Brazil  (Nov 26, 2014)
  Eisai Launches Antiepileptic Drug Fycompa in Hong Kong  (Nov 21, 2014)
  Eisai's Ranking Significantly Increases in the Access to Medicine Index 2014  (Nov 17, 2014)



 Recent  Drugs & OTC News   
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)

More Drugs & OTC news...

 Recent  Medical News   
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)

More Medical news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)